A vial of<unk>  solution for injection<unk>  (also known as<unk> , code name Ro 15-1788) is a selective GABAA receptor antagonist administered via injection, otic insertion, or intranasally. Therapeutically, it acts as both an antagonist and antidote to benzodiazepines (particularly in cases of overdose), through competitive inhibition. It was first characterized in 1981, and was first marketed in 1987 by Hoffmann-La Roche under the trade name Anexate. However, it did not receive FDA approval until December 20, 1991. The developer lost its exclusive patent rights in 2008; so at present, generic formulations of this drug are available. Intravenous<unk>  is primarily used to treat benzodiazepine overdoses and to help reverse anesthesia. Administration of<unk>  by sublingual lozenge and topical cream has also been tested.
Flumazenil
Bremazocine
Pentazocine
Dezocine
Ketazolam
Naloxone
Eptazocine
Trimetazidine